FLUOXETINE-GA 20 mg - Actavis think smart medicine
... at 40 mg/day, plasma concentrations of fluoxetine in the range of 91 to 302 nanogram/mL and norfluoxetine in the range of 72 to 258 nanogram/mL have been observed. Plasma concentrations of fluoxetine were higher than those predicted by single dose studies, presumably because its metabolism is not pr ...
... at 40 mg/day, plasma concentrations of fluoxetine in the range of 91 to 302 nanogram/mL and norfluoxetine in the range of 72 to 258 nanogram/mL have been observed. Plasma concentrations of fluoxetine were higher than those predicted by single dose studies, presumably because its metabolism is not pr ...
Hydrocodone Bitartrate
... 2.5 mg every 4-6 hours as needed >2-14 years of age (up to 31 kg): ~3.75 mg every 4-6 hours as needed >14 years of age (up to 45 kg): 5 mg every 4-6 hours as needed > 14 years of age (>46kg): ~7.5 mg every 4-6 hours as needed ...
... 2.5 mg every 4-6 hours as needed >2-14 years of age (up to 31 kg): ~3.75 mg every 4-6 hours as needed >14 years of age (up to 45 kg): 5 mg every 4-6 hours as needed > 14 years of age (>46kg): ~7.5 mg every 4-6 hours as needed ...
Antiviral Agents, Topical Therapeutic Class Review (TCR) September 20, 2012
... cream, 5% acyclovir cream, or placebo at the earliest sign of a cold sore recurrence. The subjects had, on average, 5.6 episodes of herpes labialis in the previous 12 months. The cream was applied five times per day for five days. A total of 1,443 patients experienced a recurrence and initiated trea ...
... cream, 5% acyclovir cream, or placebo at the earliest sign of a cold sore recurrence. The subjects had, on average, 5.6 episodes of herpes labialis in the previous 12 months. The cream was applied five times per day for five days. A total of 1,443 patients experienced a recurrence and initiated trea ...
Effects of terbutaline and atenolol ... airways in asthmatic patients J.W.J. Lammers, Folgering,
... Accepted for publication January 11, 1988. ...
... Accepted for publication January 11, 1988. ...
Newer Antihistamines
... Background: Several second-generation antihistamines have documented anti-inflammatory effects which appear independent of H1-receptor blockade. We investigated the inhibitory effect of cetirizine and its active enantiomer levocetirizine on eosinophil transendothelial migration (TEM) through monolay ...
... Background: Several second-generation antihistamines have documented anti-inflammatory effects which appear independent of H1-receptor blockade. We investigated the inhibitory effect of cetirizine and its active enantiomer levocetirizine on eosinophil transendothelial migration (TEM) through monolay ...
epilepsy - Government Madurai Medical College
... Mechanisms intrinsic to the neuron include changes in the conductance of ion channels, response characteristics of membrane receptors, cytoplasmic buffering, second-messenger systems, and protein expression as determined by gene transcription, translation, and posttranslational modification. Mechan ...
... Mechanisms intrinsic to the neuron include changes in the conductance of ion channels, response characteristics of membrane receptors, cytoplasmic buffering, second-messenger systems, and protein expression as determined by gene transcription, translation, and posttranslational modification. Mechan ...
Cymbalta - GuildLink
... Prevention of depressive relapse: Patients responding to 12 weeks of acute treatment with open-label duloxetine at a dose of 60 mg once daily were randomly assigned to either duloxetine 60 mg once daily or placebo for a further 6 months (continuation phase) and time to relapse in each group was comp ...
... Prevention of depressive relapse: Patients responding to 12 weeks of acute treatment with open-label duloxetine at a dose of 60 mg once daily were randomly assigned to either duloxetine 60 mg once daily or placebo for a further 6 months (continuation phase) and time to relapse in each group was comp ...
[Product Monograph Template
... NATESTO is not indicated for use in women, due to lack of evaluation and possible virilizing effects (see CONTRAINDICATIONS). NATESTO is contraindicated during pregnancy or in women who may become pregnant. Testosterone is teratogenic and may cause fetal harm. If this drug is used during pregnancy o ...
... NATESTO is not indicated for use in women, due to lack of evaluation and possible virilizing effects (see CONTRAINDICATIONS). NATESTO is contraindicated during pregnancy or in women who may become pregnant. Testosterone is teratogenic and may cause fetal harm. If this drug is used during pregnancy o ...
Top 300 Drug List
... Finish course as prescribed. No CYP 3A4 inhibition. QT prolongation possible. Opthalmic solution, Azasite, is refrigerated. Finish course as prescribed. May impart metallic taste. Inhibits CYP 3A4. QT prolongation possible. Available in many dosage forms (oral, topical, vaginal suppository, powder f ...
... Finish course as prescribed. No CYP 3A4 inhibition. QT prolongation possible. Opthalmic solution, Azasite, is refrigerated. Finish course as prescribed. May impart metallic taste. Inhibits CYP 3A4. QT prolongation possible. Available in many dosage forms (oral, topical, vaginal suppository, powder f ...
DP-Anastrozole
... reported with anastrozole are similar to those reported with other aromatase inhibitors such as tamoxifen. Most of the adverse events are mild or moderate in nature and do not require modification or discontinuation of therapy. ...
... reported with anastrozole are similar to those reported with other aromatase inhibitors such as tamoxifen. Most of the adverse events are mild or moderate in nature and do not require modification or discontinuation of therapy. ...
Sinemet® CR Product Monograph
... carbidopa) and other dopaminergic agents have reported suddenly falling asleep while engaged in activities of daily living, including the driving of a car, which has sometimes resulted in accidents. Although some of the patients reported somnolence while on SINEMET® CR, others perceived that they ha ...
... carbidopa) and other dopaminergic agents have reported suddenly falling asleep while engaged in activities of daily living, including the driving of a car, which has sometimes resulted in accidents. Although some of the patients reported somnolence while on SINEMET® CR, others perceived that they ha ...
Product Monograph
... of regular narcotic therapy. When instituting prolonged therapy for chronic pain the routine prescription of antiemetic should be considered. Patients taking the equivalent of a single dose of 20 mg or more of morphine every 4 hours (60 mg of M-ESLON Capsules (Morphine Sulfate Extended Release Capsu ...
... of regular narcotic therapy. When instituting prolonged therapy for chronic pain the routine prescription of antiemetic should be considered. Patients taking the equivalent of a single dose of 20 mg or more of morphine every 4 hours (60 mg of M-ESLON Capsules (Morphine Sulfate Extended Release Capsu ...
product monograph - Eli Lilly Canada
... with treatment. Patients should be instructed to contact their physician should they experience any side effects or discomfort during treatment with somatropin (see Information for Patients and Part III: CONSUMER INFORMATION). Concomitant glucocorticoid therapy at supraphysiologic doses may inhibit ...
... with treatment. Patients should be instructed to contact their physician should they experience any side effects or discomfort during treatment with somatropin (see Information for Patients and Part III: CONSUMER INFORMATION). Concomitant glucocorticoid therapy at supraphysiologic doses may inhibit ...
Procedural Sedation and Analgesia Guideline
... underwent procedural sedation and analgesia9. Of the 905 patient for whom fasting status was documented, 509 patients (58%) did not meet the ASA/ AAP fasting guidelines. There were no documented episodes of aspiration in this study. The study also showed no difference in rate of adverse events betwe ...
... underwent procedural sedation and analgesia9. Of the 905 patient for whom fasting status was documented, 509 patients (58%) did not meet the ASA/ AAP fasting guidelines. There were no documented episodes of aspiration in this study. The study also showed no difference in rate of adverse events betwe ...
Furosemide - Circulation
... potassium, and chloride and weight loss induced over a 24-hour period in nine edematous patients by oral administration of a standard dose of furosemide. Increase in daily excretion of sodium ranged from 26 to ...
... potassium, and chloride and weight loss induced over a 24-hour period in nine edematous patients by oral administration of a standard dose of furosemide. Increase in daily excretion of sodium ranged from 26 to ...
Assessing Statin Therapy: What are Their Differences? - Pri-Med
... Masana L. Pitavastatin - from clinical trials to clinical practice. Atheroscler Suppl. 2010 Dec;11(3):15-22. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; for the National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Associati ...
... Masana L. Pitavastatin - from clinical trials to clinical practice. Atheroscler Suppl. 2010 Dec;11(3):15-22. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; for the National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Associati ...
Endophthalmitis Prophylaxis – Implications of the European Society
... one to two drops in the affected eye(s) every two hours up to 8 times per day while awake for the fi rst two days and then four times daily on days 3 through to 5. If different topical ocular medications are used concomitantly, at least a 15-minute interval is required between instillations. To preve ...
... one to two drops in the affected eye(s) every two hours up to 8 times per day while awake for the fi rst two days and then four times daily on days 3 through to 5. If different topical ocular medications are used concomitantly, at least a 15-minute interval is required between instillations. To preve ...
Phebra Benztropine 2 mg in 2 mL Injection
... In large doses, the drug may cause complaints of weakness and inability to move particular muscle groups. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment may be required. Mental confusion and excitement may occur ...
... In large doses, the drug may cause complaints of weakness and inability to move particular muscle groups. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment may be required. Mental confusion and excitement may occur ...
Each tablet contains 5 mg of aripiprazole
... expected benefit clearly justifies the potential risk to the foetus. Aripiprazole was excreted in the milk of treated rats during lactation. It is not known whether aripiprazole is excreted in human milk. Patients should be advised not to breast feed if they are taking aripiprazole. ...
... expected benefit clearly justifies the potential risk to the foetus. Aripiprazole was excreted in the milk of treated rats during lactation. It is not known whether aripiprazole is excreted in human milk. Patients should be advised not to breast feed if they are taking aripiprazole. ...
(Dosing, switching, and other practical information).
... Percent of Patients Reporting Placebo (n=1166) ...
... Percent of Patients Reporting Placebo (n=1166) ...
Balsalazide disodium for the treatment of ulcerative colitis Drug Profile
... whereas 30% of the total 5-ASA component is excreted in the urine and 46% in the feces [10,16]. Given that balsalazide relies on colonic bacteria for its activity, it has been speculated whether concomitant antibiotic treatment or an individual’s colonic flora can affect its efficacy. Although there ...
... whereas 30% of the total 5-ASA component is excreted in the urine and 46% in the feces [10,16]. Given that balsalazide relies on colonic bacteria for its activity, it has been speculated whether concomitant antibiotic treatment or an individual’s colonic flora can affect its efficacy. Although there ...
AusPAR: Triptorelin acetate
... aqueous solution at a concentration of 100 µg/1 mL of the acetate salt (95.6 µg/1 mL of the free triptorelin). Although as a new chemical entity the product should not be labelled in terms of the salt (triptorelin acetate), but in terms of the free active entity (triptorelin), the sponsor argued tha ...
... aqueous solution at a concentration of 100 µg/1 mL of the acetate salt (95.6 µg/1 mL of the free triptorelin). Although as a new chemical entity the product should not be labelled in terms of the salt (triptorelin acetate), but in terms of the free active entity (triptorelin), the sponsor argued tha ...
Antiseizure drugs
... Its mechanism of action and clinical uses are similar to that of phenytoin. However, it is also commonly used for Rx of mania and trigeminal neuralgia. Pharmacokinetics available as an oral form only Well absorbed 80 % protein bound Strong inducing agent including its own (can lead to failure of oth ...
... Its mechanism of action and clinical uses are similar to that of phenytoin. However, it is also commonly used for Rx of mania and trigeminal neuralgia. Pharmacokinetics available as an oral form only Well absorbed 80 % protein bound Strong inducing agent including its own (can lead to failure of oth ...
EXFORGE 5/80 EXFORGE 5/160 EXFORGE 10/160
... antihypertensive activity occurs within 2 hours and the peak reduction in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dose administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally atta ...
... antihypertensive activity occurs within 2 hours and the peak reduction in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dose administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally atta ...
Guidelines of care for the management of psoriasis and psoriatic arthritis F
... prerequisite to starting a systemic therapy for psoriasis, a subset of patients with limited disease have debilitating symptoms. For example, although severe psoriasis of the palms and soles or severe scalp psoriasis affects less than 5% of the body surface area, the significant negative affect on t ...
... prerequisite to starting a systemic therapy for psoriasis, a subset of patients with limited disease have debilitating symptoms. For example, although severe psoriasis of the palms and soles or severe scalp psoriasis affects less than 5% of the body surface area, the significant negative affect on t ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.